Two differentiated clinical stage biologic therapeutic candidates.

Drawing on the breadth and depth of our team’s experience and abilities while utilizing our proprietary technology, we’ve developed a promising pipeline that we believe has attributes and mechanisms of action that are superior to the field’s existing approaches.

Our Pipeline

Our multivalent, TNF superfamily candidates are precisely engineered to drive optimized receptor clustering.

The Candidates

Preclinical

Phase 1

Phase 2

Phase 3

Ozekibart (INBRX-109)

Our Tetravalent DR5 Agonist

Oncology

Ozekibart (INBRX-109) is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more Phase 1 Trial Phase 2 Trial

Inbrx 109

INBRX-106

Our Hexavalent OX40 Agonist

Oncology

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov

Inbrx 106